Literature DB >> 19209086

Polymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma.

Zhen Zhen Zhao1, David L Duffy, Shane A Thomas, Nicholas G Martin, Nicholas K Hayward, Grant W Montgomery.   

Abstract

The prevalence of cutaneous malignant melanoma (CMM) has increased significantly in most Caucasian populations in recent decades. Both genetic and environmental risk factors are involved in the development of CMM. A germline mutation in the syntaxin 17 (STX17) gene of horses was recently identified, which causes premature hair graying and is associated with susceptibility to melanoma. We hypothesized that common germline variants in the STX17 gene might be associated with a predisposition to human CMM or might interact with other melanoma risk genes. We genotyped 26 tagging single nucleotide polymorphisms (SNPs) across the STX17 gene region in an Australian sample of 1560 melanoma cases and 1650 controls and performed logistic regression analysis to identify potential SNP interactions in a combined dataset. Our results do not support an association between CMM and any of the STX17 SNPs and provide no evidence for interactions between the melanoma risk SNP rs910873 on chromosome 20 and any of the STX17 SNPs. We conclude that common variants in the STX17 gene region do not play a key role in the pathogenesis of human melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19209086      PMCID: PMC3665505          DOI: 10.1097/CMR.0b013e328322fc45

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  37 in total

Review 1.  The current epidemiology of cutaneous malignant melanoma.

Authors:  Marianne Berwick; Charles Wiggins
Journal:  Front Biosci       Date:  2006-05-01

2.  Common sequence variants on 20q11.22 confer melanoma susceptibility.

Authors:  Kevin M Brown; Stuart Macgregor; Grant W Montgomery; David W Craig; Zhen Zhen Zhao; Kelly Iyadurai; Anjali K Henders; Nils Homer; Megan J Campbell; Mitchell Stark; Shane Thomas; Helen Schmid; Elizabeth A Holland; Elizabeth M Gillanders; David L Duffy; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Dietrich A Stephan; Anne E Cust; David Whiteman; Adele Green; Håkan Olsson; Susana Puig; Paola Ghiorzo; Johan Hansson; Florence Demenais; Alisa M Goldstein; Nelleke A Gruis; David E Elder; Julia Newton Bishop; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; Nicholas G Martin; Jeffrey M Trent; Graham J Mann; Nicholas K Hayward
Journal:  Nat Genet       Date:  2008-05-18       Impact factor: 38.330

Review 3.  Sunlight and cutaneous malignant melanoma: evidence for and against causation.

Authors:  H K Koh; B E Kligler; R A Lew
Journal:  Photochem Photobiol       Date:  1990-06       Impact factor: 3.421

4.  Hereditary malignant melanoma: a unifying etiologic hypothesis.

Authors:  H T Lynch; R M Fusaro
Journal:  Cancer Genet Cytogenet       Date:  1986-02-15

5.  PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines.

Authors:  P M Pollock; G J Walker; J M Glendening; T Que Noy; N C Bloch; J W Fountain; N K Hayward
Journal:  Melanoma Res       Date:  2002-12       Impact factor: 3.599

Review 6.  Epidemiology and etiology of malignant melanoma.

Authors:  F J Lejeune
Journal:  Biomed Pharmacother       Date:  1986       Impact factor: 6.529

7.  The Queensland Study of Melanoma: environmental and genetic associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures.

Authors:  Amanda J Baxter; Maria Celia Hughes; Marina Kvaskoff; Victor Siskind; Sri Shekar; Joanne F Aitken; Adele C Green; David L Duffy; Nicholas K Hayward; Nicholas G Martin; David C Whiteman
Journal:  Twin Res Hum Genet       Date:  2008-04       Impact factor: 1.587

8.  A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse.

Authors:  Gerli Rosengren Pielberg; Anna Golovko; Elisabeth Sundström; Ino Curik; Johan Lennartsson; Monika H Seltenhammer; Thomas Druml; Matthew Binns; Carolyn Fitzsimmons; Gabriella Lindgren; Kaj Sandberg; Roswitha Baumung; Monika Vetterlein; Sara Strömberg; Manfred Grabherr; Claire Wade; Kerstin Lindblad-Toh; Fredrik Pontén; Carl-Henrik Heldin; Johann Sölkner; Leif Andersson
Journal:  Nat Genet       Date:  2008-07-20       Impact factor: 38.330

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  The NR4A subgroup: immediate early response genes with pleiotropic physiological roles.

Authors:  Megan A Maxwell; George E O Muscat
Journal:  Nucl Recept Signal       Date:  2006-02-08
View more
  3 in total

1.  circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma.

Authors:  Peng Li; Runjie Song; Fan Yin; Mei Liu; Huijiao Liu; Shuoqian Ma; Xiaomeng Jia; Xiaohui Lu; Yuting Zhong; Lei Yu; Xiru Li; Xiangdong Li
Journal:  Mol Ther       Date:  2021-08-25       Impact factor: 11.454

Review 2.  Cross-species models of human melanoma.

Authors:  Louise van der Weyden; E Elizabeth Patton; Geoffrey A Wood; Alastair K Foote; Thomas Brenn; Mark J Arends; David J Adams
Journal:  J Pathol       Date:  2015-10-09       Impact factor: 7.996

3.  Modulation of stress and immune response by Amblyomin-X results in tumor cell death in a horse melanoma model.

Authors:  Flavio Lichtenstein; Asif Iqbal; Sonia Elisabete Alves de Lima Will; Rosemary Viola Bosch; Carlos DeOcesano-Pereira; Mauricio Barbugiani Goldfeder; Roger Chammas; Carlos Eduardo Madureira Trufen; Katia Luciano Pereira Morais; Jean Gabriel de Souza; Renato Jose Mendonça Natalino; Inacio Junqueira de Azevedo; Milton Yutaka Nishiyama Junior; Ursula Oliveira; Francisco Ivanio Arruda Alves; Jaqueline Mayara Araujo; Aline Ramos Maia Lobba; Ana Marisa Chudzinski-Tavassi
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.